A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

Clinical Infectious Diseases

Volumn 43, Issue 3, 2006, Pages 357-364

  Ritmeijer, Koert ^a   Dejenie, Abren ^a   Assefa, Yibeltal ^b   Hundie, Tadesse Beyene ^a   Mesure, Jo ^a   Boots, Gerry ^a   Den Boer, Margriet ^a   Davidson, Robert N ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Tigray Bureau of Health   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; STIBOGLUCONATE SODIUM;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ETHIOPIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIA DONOVANI; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEROPREVALENCE; SPLENOMEGALY; VISCERAL LEISHMANIASIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; COMORBIDITY; ETHIOPIA; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; PREVALENCE; TREATMENT OUTCOME;

EID: 33746083226     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505217     Document Type: Article

References (25)

1. Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R1 Soc Trop Med Hyg 2001; 95:668-72.
2. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health 2003; 8:733-9.
3. Thakur CP, Sinha GP, Pandey AK, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92: 561-9.
4. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
5. Davidson, RN. AIDS and leishmaniasis. Genitourin Med 1997; 73:237-9.
6. Laguna F, Adrados M, Alvar J, et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16:898-903.
7. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13:1063-9.
8. Croft SL, Neal RA, Thornton EA, Herrmann DB. The activity of alkyl phosphorylcholines and related derivates against Leishmania donovani Biochem Pharmacol 1987; 36:2633-6.
9. Kuhlencord A, Maniera T, Bible H, Linger C. Hexadecyl-phosphocholine; oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36:1630-4.
10. Sundar S, Rosenkaimker F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-3.
11. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93: 589-97.
12. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
13. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31:1110-3.
14. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
15. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan: visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95(Suppl 1):S27-58.
16. World Health Organization (WHO). Manual on visceral leishmaniasis [WHO/Leish/96.40]. Geneva, Switzerland: WHO, 1996.
17. Médecins Sans Frontières (MSF). Manual for diagnosis and treatment of kala-azar under field conditions. Amsterdam, The Netherlands: MSF, 2004.
18. Meredith SE, Kroon NC, Sondorp E, et al. Leish-KIT, a stable direct agglutination test based on freeze dried antigen for serodiagnosis of visceral leishmaniasis. J Clin Microbiol 1995; 33:1742-5.
19. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. 2004. Available at: http://www.wma.net/e/policy/pdf/17c.pdf. Accessed October 2002.
20. Delgado J, Macias J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. Am J Trop Med Hyg 1999; 61:766-9.
21. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine 2001; 80: 54-73.
22. Medrano FJ, Canavate C, Leal M, Rey C, Lissen E, Alvar J. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59:155-62.
23. Sundar S, Murray HW. Availability of miltefosine for treatment of kalaazar in India. Bull World Health Organ 2005; 83:394-5.
24. Molina R, Lohse JM, Pulido F, Laguna F, Lopez-Velez R, Alvar J. Infection of sand flies by humans co-infected with Leishmania infantum and human immunodeficiency virus. Am J Trop Med Hyg 1999; 60: 51-3.
25. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928-34.